Liquid Biopsy Market to Witness CAGR of 21.7% Rise in Value Share During the Period 2016 – 2026
The global demand for liquid biopsy test is increasing as a result of rapid adoption of new technologies and increasing adverse patient-related cases. In its report titled Liquid Biopsy Market – Global Industry Analysis and Opportunity Assessment, 2016–2026, FMI has presented an in-depth analysis of the liquid biopsy market for forecast period 2016–2026. Developed economies are witnessing rapid adoption of liquid biopsy test as it provides proper decision support regarding anti-cancerous drugs to doctors, physicians and oncologists. As well expected, North America is expected to dominate the overall liquid biopsy market in terms of revenue generation throughout the forecast period. A false positive occurs when the sample indicates cancer, even if no danger is actually present – either because the tumor has already been caught or eradicated by the immune system or because it continues to grow so slowly that it will not harm the patient in his or her lifetime. False positive results can lead to overtreatment, which may do more damage than good in the long run.
Download the sample copy of Report with table of contents and Figures @ https://www.futuremarketinsights.com/reports/sample/rep-gb-5593
In-Depth Analysis of the Global Liquid Biopsy Market
Key segments in the liquid biopsy market are circulating tumour cells, circulating tumour nucleic acid and exosomes, in which the circulating tumour cells biomarkers is expected to hold major share in the liquid biopsy market over the forecast period, as CTCs have enhanced clinical applications which include prediction of cancer prognosis; selection and monitoring of therapeutic treatment; and drug targeted therapy. In the liquid biopsy market, North America is expected to be the most lucrative regional market in terms of revenue generation, followed by Western Europe. Ageing population in Japan and rising incidence of cancers are factors expected to fuel the adoption of liquid biopsy procedure and drive the growth of the liquid biopsy market in Japan. The liquid biopsy market in APEJ is expected to witness significant growth due to increasing awareness and increasing prevalence of cancer in the region. However, limited access to financial resources and lack of effective R&D are factors expected to dent the revenue growth of the liquid biopsy market in the region.
Currently, liquid biopsy is gaining huge acceptance by diagnostic laboratories and research institutes for diagnosis of various chronic diseases including cancer. Critical information about cancer can be detected through liquid biopsy procedures, involving a biofluid sample – blood or urine. These liquid biopsy tests can eliminate numerous problems associated with tissue biopsies. Also, liquid biopsy provides a detailed view of a tumor’s genetic makeup including complete molecular information of a tumor. Thus providing huge scope for the companies to launch innovative tests in the liquid biopsy market.
Preview Analysis of Liquid Biopsy Market: Rising Cases of Lung Cancer Fuelling Adoption of Liquid Biopsy Across the World: Global Industry Analysis (2012 – 2016) and Opportunity Assessment (2017 – 2027): https://www.futuremarketinsights.com/reports/liquid-biopsy-market-112017
Strategies Adopted by Companies in the Global Liquid Biopsy Market
The companies in the liquid biopsy market are introducing innovative molecular diagnostic tests as means for boosting incremental innovation. These innovative molecular diagnostic tests are minimally invasive. Also, liquid biopsy tests provide less-expensive way to monitor patients throughout treatment. For example, in June 2016, Trovagene developed Trovera – a urine-based liquid biopsy test to detect and monitor cancer. This eliminates the need to have repeat surgical biopsies. Genomic Health, Inc. launched a liquid biopsy test called Oncotype SEQ Liquid Select to detect genomic alterationsm with late-stage lung, breast, colon, melanoma, ovarian or gastrointestinal cancer.
Buy this report @ https://www.futuremarketinsights.com/checkout/5593
Liquid biopsy companies are partnering with pharmaceutical companies. Major liquid biopsy diagnostic companies are entering into strategic alliances with pharmaceutical companies with the objective to develop anti-cancer drugs and liquid biopsy tests in order to attain leadership position in the liquid biopsy market. Biocept, Inc. a liquid biopsy company entered into a services agreement with a biopharmaceutical company to develop targeted liquid biopsy tests for multiple tumor types and molecular targets. Companies Biocartis and Merck KGaA signed a collaborative pact to develop and commercialize a new liquid biopsy RAS biomarker test in 2016 – to aid patients with metastatic colorectal cancer.
Our advisory services are aimed at helping you with specific, customized insights that are relevant to your specific challenges. Let us know about your challenges and our trusted advisors will connect with you: https://www.futuremarketinsights.com/askus/rep-gb-5593
More from Healthcare, Pharmaceuticals and Medical devices :
About Us
Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights and an aerial view of the competitive framework and future market trends.
Contact Us
Mr. Abhishek Budholiya
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
T (UK): + 44-(0)-20-7692-8790
Sales: sales@futuremarketinsights.com
Press Office: Press@futuremarketinsights.com
Blog: Market Research Blog
Website: https://www.futuremarketinsights.com/
Editor Details
-
Company:
- MARKITWIRED
- Website:
